NTLA : Insider Transactions for Intellia Therapeutics, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Intellia Therapeutics, Inc. (NTLA)

$24.46

0.40 (1.61%) as of 4:30 Fri 5/10

Download

Exchange:

N/A

Security Type:

Common

Shares Out:

89,554,000

Market Cap:

2.19(B)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$20.02 - $46.03

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

Company Profile Intellia Therapeutics is a genome editing company focused on developing therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To realize the transformative potential of CRISPR/Cas9-based technologies, Co. is building a range of genome editing company, by utilizing its modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	2,902	53,430	61,187	62,275
Total Sell Value	$95,737	$1,583,155	$1,913,663	$1,961,404
Total People Sold	2	7	8	8
Total Sell Transactions	2	10	15	16
End Date	2024-02-11	2023-11-10	2023-05-12	2022-05-12

Adjust Filter Settings

Records found: 245

Page 9 of 10

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Formela Jean Francois

Director

– • –

2018-05-16

4

AS

$25.04

$167,389

I/I

(6,686)

0

-

Leonard John M.

President and CEO

• • –

2018-05-14

4

AS

$24.00

$201,600

I/I

(8,400)

0

-

EVP, Chief Financial Officer

• – –

2018-03-28

4

OE

$13.48

$107,840

D/D

8,000

21,400

-

Director

– • –

2018-03-23

4

A

$24.05

$9,861

D/D

410

5,410

-

Formela Jean Francois

Director

– • –

2018-03-20

4

S

$23.78

$936,743

I/I

(39,245)

0

-

Caribou Biosciences, Inc.

– – •

2018-01-29

4

S

$26.78

$14,746,273

I/I

(550,645)

3,994,355

-

10% Owner

– – •

2017-12-12

4

S

$18.30

$27,870,900

D/D

(1,523,000)

4,129,903

-

Bermingham Nessan

President & CEO

• • –

2017-12-08

4

AS

$20.82

$1,960,151

D/D

(94,143)

458,250

-

Bermingham Nessan

President & CEO

• • –

2017-12-07

4

AS

$21.05

$2,771,867

D/D

(131,140)

552,393

-

Bermingham Nessan

President & CEO

• • –

2017-12-06

4

AS

$20.28

$2,268,001

D/D

(111,500)

683,533

-

EVP, Chief Financial Officer

• – –

2017-11-03

4

A

$22.04

$110,217

D/D

5,000

13,400

-

Caribou Biosciences, Inc.

– – •

2017-09-13

4

S

$0.00

$0

I/I

(1,048,846)

4,545,000

-

Formela Jean Francois

Director

– • –

2017-07-11

4

S

$16.07

$1,285,560

I/I

(80,000)

3,579,788

-

Atlas Venture Associates Ix, Llc

10% Owner

– – •

2017-07-11

4

S

$16.07

$1,285,560

D/D

(80,000)

3,579,788

-

Formela Jean Francois

Director

– • –

2017-07-10

4

S

$16.17

$646,888

I/I

(40,000)

3,659,788

-

Atlas Venture Associates Ix, Llc

10% Owner

– – •

2017-07-10

4

S

$16.17

$646,888

D/D

(40,000)

3,659,788

-

Formela Jean Francois

Director

– • –

2017-07-07

4

S

$16.77

$502,992

I/I

(30,000)

3,699,788

-

Atlas Venture Associates Ix, Llc

10% Owner

– – •

2017-07-07

4

S

$16.77

$502,992

D/D

(30,000)

3,699,788

-

Director

– • –

2017-06-02

4

A

$12.42

$62,100

D/D

5,000

5,000

-

EVP, Chief Financial Officer

• – –

2017-06-02

4

A

$12.37

$103,938

D/D

8,400

8,400

-

Director

– • –

2017-06-01

4

A

$11.99

$59,925

D/D

5,000

5,000

-

Leonard John M.

EVP, R&D

• • –

2017-06-01

4

A

$12.06

$101,322

I/I

8,400

8,400

-

EVP, General Counsel & Ops

• – –

2017-06-01

4

A

$12.03

$101,075

D/D

8,400

8,994

-

Bermingham Nessan

President & CEO

• • –

2017-06-01

4

A

$11.95

$100,379

D/D

8,400

795,033

-

Atlas Venture Associates Ix, Llc

10% Owner

– – •

2017-03-10

4

S

$14.06

$77,410

D/D

(5,504)

0

-

245 Records found	1 2 3 4 5 6 7 8 9 Next	Page 9 of 10

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.